2. Academic Validation
  3. Tiragolumab Impresses in Multiple Trials

Tiragolumab Impresses in Multiple Trials

  • Cancer Discov. 2020 Aug;10(8):1086-1087. doi: 10.1158/2159-8290.CD-NB2020-063.
PMID: 32576590 DOI: 10.1158/2159-8290.CD-NB2020-063
Abstract

The TIGIT inhibitor tiragolumab, alone or in combination with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically significant results in multiple solid malignancies-most notably non-small cell lung Cancer.

Figures
Products